FDA advisory committee adopts a positive review of Abbott’s Absorb stent
16 March 2016 | By Victoria White
Absorb is a first-of-its-kind bioresorbable device for the treatment of coronary artery disease. It dissolves completely after 2 to 3 years...
List view / Grid view
News
Freedom to evolve with Tecan’s Freedom EVO® 75
15 March 2016 | By Tecan
Researchers at the Complutense University of Madrid are using directed evolution techniques to develop new enzymes for a variety of bioprocessing applications...
Quotient Clinical incorporates Japanese bridging into a Translational Pharmaceutics® program
15 March 2016 | By Quotient Clinical
Quotient Clinical has announced the completion of its first clinical program involving Japanese healthy volunteers...
Verona Pharma announces positive headline data from RPL554 trial
15 March 2016 | By Victoria White
The study met its primary objective, with nebulised RPL554 demonstrating a dose-dependent bronchodilator response in asthma patients...
Peptide vaccines and immuno-oncology products hold promise in glioblastoma
15 March 2016 | By Victoria White
According to GlobalData analysts, hopes for improved therapies for glioblastoma have turned to Opdivo and drugs combining peptide vaccines with immuno-oncology products...
Lilly changes the primary endpoint of the EXPEDITION3 Alzheimer’s trial
15 March 2016 | By Victoria White
Lilly has made a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer's dementia...
First patient treated in trial of ReNeuron’s retinitis pigmentosa cell therapy
ReNeuron has demonstrated that its Human Retinal Progenitor Cells (hRPCs) improve visual acuity in preclinical models of retinal degeneration...
FDA grants priority review to Roche’s atezolizumab in urothelial carcinoma
15 March 2016 | By Victoria White
The priority review is based on results of the IMvigor 210 study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression.
First real-world evidence comparing an SGLT2 inhibitor with DPP-4 inhibitors
15 March 2016 | By Victoria White
A real-world study showed use of Invokana (canagliflozin) is associated with significantly greater improvements in blood glucose control compared to DPP-4 inhibitors...
Forecasting in dynamic Oncology Markets
14 March 2016 | By Black Swan Analysis
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month...
Wickham Labs to Exhibit at Med-Tech Innovation Expo 2016
14 March 2016 | By Wickham Laboratories Ltd
Wickham Laboratories Ltd will be on Stand 12 at the upcoming Med-Tech Innovation Expo at the Ricoh Arena in Coventry, April 20-21...
Wickham Labs to Exhibit at Making Pharmaceuticals 2016
14 March 2016 | By Wickham Laboratories Ltd
Wickham Laboratories Ltd will exhibit on Stand 307 at Making Pharmaceuticals, April 26-27...
Abiraterone acetate plus prednisone shows survival benefit in early mCRPC
14 March 2016 | By Victoria White
In a study, abiraterone acetate plus prednisone provided an 11.8 months overall survival benefit compared to an active control of placebo plus prednisone...
GW announces positive results for Epidiolex in Dravet syndrome
14 March 2016 | By Victoria White
Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo...
EMA to review Gilead’s Zydelig over safety concerns
14 March 2016 | By Victoria White
The European Medicines Agency's review follows concerns over serious adverse events in ongoing clinical trials of Zydelig (idelalisib)...
